- Home
- CANF vs FDSB Comparison
CANF vs FDSB Comparison
Compare CANF & FDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- FDSB
- Stock Information
- Founded
- CANF 1994
- FDSB 1926
- Country
- CANF Israel
- FDSB United States
- Employees
- CANF N/A
- FDSB N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- FDSB
- Sector
- CANF Health Care
- FDSB
- Exchange
- CANF Nasdaq
- FDSB NYSE
- Market Cap
- CANF 13.5M
- FDSB 68.7M
- IPO Year
- CANF N/A
- FDSB N/A
- Fundamental
- Price
- CANF $1.02
- FDSB $12.51
- Analyst Decision
- CANF Strong Buy
- FDSB
- Analyst Count
- CANF 2
- FDSB 0
- Target Price
- CANF $14.00
- FDSB N/A
- AVG Volume (30 Days)
- CANF 146.1K
- FDSB 10.9K
- Earning Date
- CANF 08-29-2025
- FDSB 08-15-2025
- Dividend Yield
- CANF N/A
- FDSB N/A
- EPS Growth
- CANF N/A
- FDSB N/A
- EPS
- CANF N/A
- FDSB 0.02
- Revenue
- CANF $674,000.00
- FDSB $12,612,000.00
- Revenue This Year
- CANF $461.72
- FDSB N/A
- Revenue Next Year
- CANF N/A
- FDSB N/A
- P/E Ratio
- CANF N/A
- FDSB $526.89
- Revenue Growth
- CANF N/A
- FDSB 40.41
- 52 Week Low
- CANF $0.98
- FDSB $9.85
- 52 Week High
- CANF $4.69
- FDSB $14.50
- Technical
- Relative Strength Index (RSI)
- CANF 39.13
- FDSB N/A
- Support Level
- CANF $0.99
- FDSB N/A
- Resistance Level
- CANF $1.09
- FDSB N/A
- Average True Range (ATR)
- CANF 0.04
- FDSB 0.00
- MACD
- CANF -0.00
- FDSB 0.00
- Stochastic Oscillator
- CANF 16.67
- FDSB 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About FDSB FIFTH DISTRICT BANCORP INC.
Fifth District Bancorp inc is a holding company of Fifth District. Fifth District portfolio consists primarily of fixed-rate one- to four-family residential mortgage loans also originate construction loans, home equity loans, home equity lines of credit, land loans, and share loans (loans secured by deposit accounts at Fifth District) and purchase commercial business loans. The company offer a variety of deposit accounts including checking accounts, money market accounts, and certificates of deposit. In addition, it offers electronic banking services including mobile banking, on-line banking, telephone banking, bill pay, and electronic funds transfer via SmartPay.